|
1. Biologie
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4.3 Dép., diag. & prono. - Industriels
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.6 Publications
|
|
|
Why Was Springer Nature’s IPO Withdrawn? [The Scholarly Kitchen]
|
|
|
|
|
|
Perhaps
the future is, and indeed much of the value will be, not about
publishing as we have known it but about research workflow services.
Through its new Dimensions product, for example, Digital Science is
positioning itself to transform the nature of content distribution and
access, one of several major areas where it is fostering entirely new
businesses.
|
|
|
|
|
|